Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow:: a microdialysis study in Swiss mice

被引:70
作者
David, DJP
Bourin, M
Jego, G
Przybylski, C
Jolliet, P
Gardier, AM
机构
[1] Univ Paris Sud, Fac Pharm, Neuropharmacol Lab, F-92296 Chatenay Malabry, France
[2] Univ Nantes, Fac Med, F-44035 Nantes, France
关键词
antidepressants; frontal cortex; microdialysis; noradrenaline; serotonin;
D O I
10.1038/sj.bjp.0705538
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 This study investigated whether a single administration of a range of doses (1, 4 and 8 mg kg(-1), i.p.) of paroxetine, citalopram or venlafaxine may simultaneously increase extracellular levels of 5-HT ([5-HT]ext) and noradrenaline ([NA]ext) by using in vivo microdialysis in the frontal cortex (FCx) of awake, freely moving Swiss mice. 2 In vivo, paroxetine induced similar increases in cortical [5-HT]ext at the three doses tested, and induced a statistically significant increase in cortical [NA]ext at 4 and 8 mg kg(-1). Citalopram increased neither [5-HT]ext nor [NA]ext at the lowest dose, but increased both neurotransmitter levels at 4 and 8 mg kg(-1). At these doses, citaloprarn induced greater increases in cortical [5-HT]ext than in [NA]ext. Venlafaxine increased [5-HT]ext and [NA]ext to about 400 and 140% of the respective basal values at 8 mg kg(-1). 3 Citalopram and paroxetine have the highest potency to increase cortical [5-HT]ext and [NA]ext, respectively. In addition, the rank of order of efficacy of these antidepressant drugs to increase [5-HT]ext hi vivo in the FCx of mice was as follows: venlafaxine > citalopram > paroxetine, while the efficacy to increase cortical [NA]ext in mice of paroxetine and citaloprarn is similar, and greater than that of venlafaxine. 4 In conclusion, extracellular levels of cortical [NA]ext increase with the highest doses of the very selective SSRI citalopram, as well as with the very potent SSRI paroxetine. Surprisingly, the SNRI venlafaxine increased cortical [5-HT]ext to a greater extent rather than [NA]ext in the range of doses studied in mice.
引用
收藏
页码:1128 / 1136
页数:9
相关论文
共 51 条
[1]   The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram [J].
Arborelius, L ;
Nomikos, GG ;
Hertel, P ;
Salmi, P ;
Grillner, P ;
Hook, BB ;
Hacksell, U ;
Svensson, TH .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 353 (06) :630-640
[2]   SELECTIVE SEROTONIN NORADRENALINE REUPTAKE INHIBITORS (SNRIS) - PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN THE TREATMENT OF DEPRESSIVE-DISORDERS [J].
ARTIGAS, F .
CNS DRUGS, 1995, 4 (02) :79-89
[3]  
BARKER EL, 1994, MOL PHARMACOL, V46, P799
[4]   Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters [J].
Béïque, JC ;
Lavoie, N ;
de Montigny, C ;
Debonnel, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 349 (01) :129-132
[5]   Effect of single and repeated administration of fluvoxamine on noradrenaline release in rat brain [J].
BenShachar, D ;
Klein, E ;
Tabak, A ;
Finberg, JPM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 332 (03) :237-243
[6]   Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study [J].
Beyer, CE ;
Boikess, S ;
Luo, B ;
Dawson, LA .
JOURNAL OF PSYCHOPHARMACOLOGY, 2002, 16 (04) :297-304
[7]   CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].
BLIER, P ;
DEMONTIGNY, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226
[8]  
Blier P, 2001, J PSYCHIATR NEUROSCI, V26, pS1
[9]   BLOCKADE BY NEWLY-DEVELOPED ANTIDEPRESSANTS OF BIOGENIC-AMINE UPTAKE INTO RAT-BRAIN SYNAPTOSOMES [J].
BOLDENWATSON, C ;
RICHELSON, E .
LIFE SCIENCES, 1993, 52 (12) :1023-1029
[10]   Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages [J].
Bourin, M ;
Colombel, MC ;
Redrobe, JP ;
Nizard, J ;
Hascoet, M ;
Baker, GB .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1998, 22 (02) :343-351